PALISADE BIO, INC.
No enriched coverage for $PALI in the last 7 days.
BlackRock, Inc. filed a Schedule 13G showing beneficial ownership of Palisade Bio, Inc. common stock as of June 30, 2026. BlackRock and its business units report 10,436,760 shares, or 6.0% of the class. It reports sole voting power over 10,326,107 shares and sole dispositive power over 10,436,760 shares.
Oppenheimer initiated coverage of Palisade Bio Inc. and said its stock offers exposure to the inflammatory bowel disease market. The company’s lead drug PALI-2108 (PDE4 inhibitor prodrug) showed positive Phase 1a/1b results. The FDA cleared its IND in June for Phase 2 ASCENTRA-UC, with enrollment in 2H 2026 and topline data in 2H 2027. Oppenheimer set a Buy rating and $8 price target.
Benzinga reports Palisade Bio’s lead drug PALI-2108, a once-daily oral PDE4 inhibitor prodrug, showed positive Phase 1a and 1b results in ulcerative colitis and fibrostenotic Crohn’s disease. The company plans an IND for Phase 2 ASCENTRA-CD in 2H 2026. Analyst Leland Gershell initiated Buy with an $8 price target; Oppenheimer projects peak U.S. sales of $2.6B UC (2040) and $2.8B fibrostenotic CD (2041).
Recent PALI coverage spans financial news, insider activity and market movers.
In the last 30 days, PALI insiders filed 1 SEC Form 4 transaction — 1 purchase ($49K) and no sales. The most active reporter was Baltera Robert Jr. with 1 filing.
A new 6.0% beneficial ownership disclosure can shift perceived control dynamics and influence near-term positioning around Palisade Bio.
Initiated coverage plus specific clinical and regulatory milestones can support near-term sentiment, but it is not a new trial readout.
Clinical development progress and a planned IND submission are incremental catalysts for PALI, but the article is largely analyst framing rather than new trial readouts.
The initiation and immediate price reaction suggest near-term momentum and sentiment tailwinds tied to the $8 target and PALI-2108 thesis.
The filing discloses an insider open-market purchase, which can be read as mild bullish sentiment but is not a fundamental catalyst by itself.
alphai scores every news story that mentions PALI with an AI model for sentiment and relevance, and aggregates insider trades from PALISADE BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BlackRock, Inc. filed a Schedule 13G showing beneficial ownership of Palisade Bio, Inc. common stock as of June 30, 2026. BlackRock and its business units report 10,436,760 shares, or 6.0% of the class. It reports sole voting power over 10,326,107 shares and sole dispositive power over 10,436,760 shares.
3 min readOppenheimer initiated coverage of Palisade Bio Inc. and said its stock offers exposure to the inflammatory bowel disease market. The company’s lead drug PALI-2108 (PDE4 inhibitor prodrug) showed positive Phase 1a/1b results. The FDA cleared its IND in June for Phase 2 ASCENTRA-UC, with enrollment in 2H 2026 and topline data in 2H 2027. Oppenheimer set a Buy rating and $8 price target.
6 min readBenzinga reports Palisade Bio’s lead drug PALI-2108, a once-daily oral PDE4 inhibitor prodrug, showed positive Phase 1a and 1b results in ulcerative colitis and fibrostenotic Crohn’s disease. The company plans an IND for Phase 2 ASCENTRA-CD in 2H 2026. Analyst Leland Gershell initiated Buy with an $8 price target; Oppenheimer projects peak U.S. sales of $2.6B UC (2040) and $2.8B fibrostenotic CD (2041).
3 min readOppenheimer initiated coverage of Palisade Bio (PALI) with an outperform rating, and the stock rose about 14% in Thursday morning trading. The firm set an $8 price target, implying 321% upside versus the July 22 close. Analyst Lelend Gershell cited potential for PALI-2108.
1 min readBaltera Robert Jr. purchased 45,000 shares of PALISADE BIO, INC. (PALI) at an average of $1.97 ($1.96–$1.99) across 2 trades over 2026-07-08 to 2026-07-09.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readBaltera Robert Jr. purchased 50,000 shares of PALISADE BIO, INC. (PALI) at an average of $2.04 ($2.03–$2.05, $0.10M total) across 2 trades over 2026-07-06 to 2026-07-07.
1 min readJones Mitchell Lawrence (Chief Medical Officer) sold 51,880 shares of PALISADE BIO, INC. (PALI) at $2.05 ($0.11M total) on 2026-07-07.
1 min readFinley John David (CEO, CFO) sold 146,798 shares of PALISADE BIO, INC. (PALI) at $2.07 ($0.30M total) on 2026-07-07.
2 min readInvesting.com’s roundup of July 6, 2026 insider trades cites buys in DLH Holdings (DLHC) ($78,479; 5,640 shares at ~$5.25), Palisade Bio (PALI) ($59,400; 30,000 shares at ~$1.98), and Cuentas (CUEN) ($2,011; 5,200 shares at ~$0.35–$0.45). Major sales include Astera Labs (ALAB) (~$60.5M), Snowflake (SNOW) (~$48.6M), Micron (MU) (~$43.4M), Arista (ANET) (~$42.7M), and Cloudflare (NET) (~$21.1M).
4 min read
